Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: An indirect comparison analysis
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Summary: Large Phase 3 clinical trials for stroke prevention in atrial fibrillation (AF) have compared non-vitamin K antagonist oral anticoagulants (NOACs) against warfarin, with the edoxaban trial only recently reported. In the absence of head to head trials directly comparing these NOACs against each other, we compared the efficacy and safety of edoxaban to other agents by an indirect comparison analysis. We performed an indirect comparison analysis of edoxaban (2 dose strategies) against apixaban (1 dose), dabigatran etexilate (2 doses) and rivaroxaban (1 dose), for their relative efficacy and safety against each other. For high-dose edoxaban vs apixaban, there were no significant differences in efficacy endpoints, mortality, myocardial infarction and major bleeding. Apixaban was associated with less major or clinically relevant non-major bleeding (hazard ratio [HR] 0.79; 95% confidence interval [CI] 0.70–0.90) and gastrointestinal bleeding (HR 0.72; 95% CI 0.53–0.99). For dabigatran 110 mg twice daily, there were no significant differences in the main efficacy or safety endpoints. Dabigatran 150 mg bid was associated with lower stroke/systemic embolism (SE) (HR 0.75; 95% CI 0.56–0.99), stroke (HR 0.73; 95% CI 0.55–0.96) and haemorrhagic stroke (HR 0.48; 95% CI 0.23–0.99). There were no significant differences between high-dose edoxaban vs rivaroxaban for efficacy endpoints or mortality, but rivaroxaban had more major and/or clinically relevant non-major bleeding. When compared to low-dose edoxaban, apixaban was associated with lower stroke/SE (HR 0.70; 95% CI 0.55–0.89), stroke (HR 0.70; 95% CI 0.55–0.92) and ischaemic stroke (HR 0.65; 95% CI 0.50–0.89), but more major bleeding (HR 1.47; 95% CI 1.20–1.80). For dabigatran 110 mg bid, there were no significant differences in the efficacy endpoints, but dabigatran 110 mg bid had higher major (and gastrointestinal) bleeding. Dabigatran 150 mg bid and rivaroxaban were associated with lower stroke/SE and ischaemic stroke, but higher bleeding rates. In the present analysis, we have provided for the first time, comparisons of efficacy and safety of edoxaban against other NOACs. Notwithstanding the significant limitations of an indirect comparison analysis, some differential effects are evident with the NOACs for stroke prevention, allowing us to allow the prescriber a ‘choice’ to be able to fit the drug to the patient clinical profile (and vice versa). Note: The review process for this paper was fully handled by Christian Weber, Editor in Chief.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215 · cited 10×
“Overall, the comorbidity in the ENGAGE-AF population was intermediate between RE-LY/ARISTOTLE and ROCKET-AF.”
BackgroundInfluentialRivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Edoxaban versus warfarin in patients with atrial fibrillation
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310907 · Cited by 5,164
Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00007 · Cited by 4,793
Bucher, H. C., Guyatt, G. H., Griffith, L. E., & Walter, S. D. (1997) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(97)00049-8 · Cited by 2,052
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
The Hokusai-VTE Investigators (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306638 · Cited by 1,869 · cited 1×
“In the HOKUSAI trial of venous thromboembolism treatment, a higher rate of MI was evident with edoxaban-treated patients compared to warfarin (14).”
BackgroundNewly identified events in the RE-LY trial
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Reilly, P. A., & Wallentin, L. (2010) · New England Journal of Medicine · doi:10.1056/nejmc1007378 · Cited by 688 · cited 9×
“Overall, the comorbidity in the ENGAGE-AF population was intermediate between RE-LY/ARISTOTLE and ROCKET-AF.”
BackgroundInfluentialWan, Y., Heneghan, C., Perera, R., Roberts, N., Hollowell, J., Glasziou, P., Bankhead, C., & Xu, Y. (2008) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.108.796185 · Cited by 514
Cited by
Stroke Prevention in Atrial Fibrillation: A Systematic Review
Lip, G. Y. H., & Lane, D. A. (2015) · JAMA · doi:10.1001/jama.2015.4369 · Cited by 322
Self-citationLip, G. Y. H., Laroche, C., Popescu, M. I., Rasmussen, L. H., Vitali-Serdoz, L., Dan, G.-A., Kalarus, Z., Crijns, H. J. G. M., Oliveira, M. M., Tavazzi, L., et al. (2015) · Europace · doi:10.1093/europace/euv269 · Cited by 151
Self-citationSkjøth, F., Nielsen, P., Larsen, T. B., & Lip, G. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-07-0565 · Cited by 106
Self-citationDrug therapy in anticoagulation: which drug for which patient?
Millar, C. M., & Laffan, M. A. (2017) · Clinical Medicine · doi:10.7861/clinmedicine.17-3-233 · Cited by 11
Metadata
- Authors
- Larsen, T. B., Rasmussen, L. H., Lip, G. Y. H., & Skjøth, F.
- Venue
- Thrombosis and Haemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 2014
- Volume
- 112
- Issue
- 05
- Pages
- 981-988
- ISSN
- 0340-6245 (ISSN-L)
- 2567-689X
- OpenAlex
- W1736100602
- Cited by
- 102
- References
- 9
- FWCI
- 16.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: An indirect comparison analysis. https://app.cochat.ai/papers/10.1160/th14-02-0118
- The paper
- Larsen, T. B., Rasmussen, L. H., Lip, G. Y. H., & Skjøth, F. (2014). Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: An indirect comparison analysis. Thrombosis and Haemostasis. https://doi.org/10.1160/th14-02-0118
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.